Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
30 hedge funds and large institutions have $51.1M invested in Eiger BioPharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 20 closing their positions.
348% more capital invested
Capital invested by funds: $11.4M → $51.1M (+$39.7M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
27% less funds holding
Funds holding: 41 → 30 (-11)
50% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 20
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $47K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$4.84M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$4.31M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.45M |
| 4 |
PA
Perceptive Advisors
New York
|
+$1.74M |
| 5 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$698K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$142K |
| 2 |
Two Sigma Investments
New York
|
-$125K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$111K |
| 4 |
Millennium Management
New York
|
-$103K |
| 5 |
Bank of New York Mellon
New York
|
-$91K |
EIGR Hedge Fund Activity: Q1 2016 in Review
30 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2016, worth a combined $51.1M — up 348% from $11.4M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of EIGR and 10 opened new positions — a net loss of 10 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $4.84M. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $142K sold.
- 30 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2016, down from 41 in Q4 2015.
- Funds reported $51.1M of Eiger BioPharmaceuticals, Inc. stock for Q1 2016, up 348% quarter-over-quarter.
- 10 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2016 and 20 closed out, a net change of -10 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2016 was RA Capital Management, an estimated $4.84M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2016 was Two Sigma Advisers, an estimated $142K sold.
Based on aggregated 13F filings for Q1 2016.